Kim E D, Smith N D, Grayhack J T
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Int Urol Nephrol. 1998;30(4):471-9. doi: 10.1007/BF02550228.
To obtain evidence of metabolic changes in the human prostate associated with prostate pathology, in particular carcinoma of the prostate, by identifying and evaluating associated changes in prostatic secretory products.
Expressed prostatic fluid (EPF) from 36 patients with carcinoma, 128 with BPH histologically confirmed, and 148 with clinical BPH was subjected to determination of protein (Lowry; UV 280 nm absorption), enzymatic (DMA modified Row procedure) acid phosphatase (AcP), and immunologically identified (Tandem-PAP immunoenzymatic assay) prostatic acid phosphatase (PAP) concentration.
The important EPF findings are the following: (1) Protein concentrations (Lowry and UV determinations) are significantly increased in carcinoma as compared to histologic BPH, (2) AcP and PAP secretions remain stable in carcinoma versus BPH, and (3) AcP and PAP/Lowry protein ratios are significantly lower with carcinoma.
These findings of increased protein and the decreased relative secretions of AcP and PAP to total protein (ratio) in EPF from patients with carcinoma compared to BPH support and help to characterize the diffuse metabolic alteration in the prostate associated with prostate carcinoma. EPF observations identify potential metabolic changes occurring in prostate carcinoma that may have potential clinical and investigative relevance.
通过识别和评估前列腺分泌产物中的相关变化，获取与前列腺病理状况，特别是前列腺癌相关的人体前列腺代谢变化的证据。
对36例前列腺癌患者、128例经组织学确诊的良性前列腺增生（BPH）患者以及148例临床诊断为BPH的患者的前列腺液（EPF）进行蛋白质（Lowry法；紫外280nm吸收法）、酶促（改良的DMA罗氏法）酸性磷酸酶（AcP）以及免疫鉴定（串联PAP免疫酶法）前列腺酸性磷酸酶（PAP）浓度的测定。
EPF的重要发现如下：（1）与组织学确诊的BPH相比，前列腺癌患者的蛋白质浓度（Lowry法和紫外测定法）显著升高；（2）与BPH相比，前列腺癌患者的AcP和PAP分泌保持稳定；（3）前列腺癌患者的AcP和PAP/Lowry蛋白比值显著降低。
与BPH相比，前列腺癌患者EPF中蛋白质增加以及AcP和PAP相对于总蛋白的相对分泌减少（比值）的这些发现，支持并有助于描述与前列腺癌相关的前列腺弥漫性代谢改变。EPF观察结果确定了前列腺癌中可能具有潜在临床和研究意义的潜在代谢变化。
